A large-scale diagnosis of the severe acute respiratory
syndrome-coronavirus-2 (SARS-CoV-2) is essential to downregulate
its spread within as well as across communities and mitigate the
current outbreak of the pandemic novel coronavirus disease 2019
(COVID-19). Herein, we report the development of a rapid (less
than 5 min), low-cost, easy-to-implement, and quantitative
paper-based electrochemical sensor chip to enable the digital
detection of SARS-CoV-2 genetic material. The biosensor uses
gold nanoparticles (AuNPs), capped with highly specific
antisense oligonucleotides (ssDNA) targeting viral nucleocapsid
phosphoprotein (N-gene). The sensing probes are immobilized on a
paper-based electrochemical platform to yield a
nucleic-acid-testing device with a readout that can be recorded
with a simple hand-held reader. The biosensor chip has been
tested using samples collected from Vero cells infected with
SARS-CoV-2 virus and clinical samples. The sensor provides a
significant improvement in output signal only in the presence of
its target—SARS-CoV-2 RNA—within less than 5 min
of incubation time, with a sensitivity of 231 (copies
μL
–1
)
−1
and
limit of detection of 6.9 copies/μL without the need for
any further amplification. The sensor chip performance has been
tested using clinical samples from 22 COVID-19 positive patients
and 26 healthy asymptomatic subjects confirmed using the
FDA-approved RT-PCR COVID-19 diagnostic kit. The sensor
successfully distinguishes the positive COVID-19 samples from
the negative ones with almost 100% accuracy, sensitivity, and
specificity and exhibits an insignificant change in output
signal for the samples lacking a SARS-CoV-2 viral target segment
(
e
.
g
., SARS-CoV,
MERS-CoV, or negative COVID-19 samples collected from healthy
subjects). The feasibility of the sensor even during the genomic
mutation of the virus is also ensured from the design of the
ssDNA-conjugated AuNPs that simultaneously target two separate
regions of the same SARS-CoV-2 N-gene.